Single nucleotide polymorphisms and genotypes of transient receptor potential ion channel and acetylcholine receptor genes from isolated B lymphocytes in myalgic encephalomyelitis/chronic fatigue syndrome patients

Sonya Marshall-Gradisnik, Samantha Johnston, Anu Chacko, Thao Nguyen, Peter Smith, Donald Staines, Sonya Marshall-Gradisnik, Samantha Johnston, Anu Chacko, Thao Nguyen, Peter Smith, Donald Staines

Abstract

Objective The pathomechanism of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is unknown; however, a small subgroup of patients has shown muscarinic antibody positivity and reduced symptom presentation following anti-CD20 intervention. Given the important roles of calcium (Ca2+) and acetylcholine (ACh) signalling in B cell activation and potential antibody development, we aimed to identify relevant single nucleotide polymorphisms (SNPs) and genotypes in isolated B cells from CFS/ME patients. Methods A total of 11 CFS/ME patients (aged 31.82 ± 5.50 years) and 11 non-fatigued controls (aged 33.91 ± 5.06 years) were included. Flow cytometric protocols were used to determine B cell purity, followed by SNP and genotype analysis for 21 mammalian TRP ion channel genes and nine mammalian ACh receptor genes. SNP association and genotyping analysis were performed using ANOVA and PLINK analysis software. Results Seventy-eight SNPs were identified in nicotinic and muscarinic acetylcholine receptor genes in the CFS/ME group, of which 35 were in mAChM3. The remaining SNPs were identified in nAChR delta (n = 12), nAChR alpha 9 (n = 5), TRPV2 (n = 7), TRPM3 (n = 4), TRPM4 (n = 1) mAChRM3 2 (n = 2), and mAChRM5 (n = 3) genes. Nine genotypes were identified from SNPs in TRPM3 (n = 1), TRPC6 (n = 1), mAChRM3 (n = 2), nAChR alpha 4 (n = 1), and nAChR beta 1 (n = 4) genes, and were located in introns and 3' untranslated regions. Odds ratios for these specific genotypes ranged between 7.11 and 26.67 for CFS/ME compared with the non-fatigued control group. Conclusion This preliminary investigation identified a number of SNPs and genotypes in genes encoding TRP ion channels and AChRs from B cells in patients with CFS/ME. These may be involved in B cell functional changes, and suggest a role for Ca2+ dysregulation in AChR and TRP ion channel signalling in the pathomechanism of CFS/ME.

Keywords: B lymphocytes; Transient receptor potential ion channels; acetylcholine; chronic fatigue syndrome; muscarinic receptor; single nucleotide polymorphisms.

References

    1. Lendvai B, Vizi ES. Nonsynaptic chemical transmission through nicotinic acetylcholine receptors. Physiol Rev 2008; 88: 333–349.
    1. Court JA, Martin-Ruiz C, Graham A, et al. Nicotinic receptors in human brain: topography and pathology. J Chem Neuroanat 2000; 20: 281–298.
    1. Felder CC. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB 1995; 9: 619–625.
    1. Brann MR, Ellis J, Jørgensen H, et al. Muscarinic acetylcholine receptor subtypes: localization and structure/function. Prog Brain Res 1993; 98: 121–127.
    1. Shen JX, Yakel JL. Nicotinic acetylcholine receptor-mediated calcium signaling in the nervous system. Acta pharmacol Sin 2009; 30: 673–680.
    1. d’Incamps BL, Ascher P. High affinity and low affinity heteromeric nicotinic acetylcholine receptors at central synapses. J Physiol 2014; 592: 4131–4136.
    1. Skok M, Grailhe R, Changeux JP. Nicotinic receptors regulate B lymphocyte activation and immune response. Eur J Pharmacol 2005; 517: 246–251.
    1. Fujii YX, Fujigaya H, Moriwaki Y, et al. Enhanced serum antigen-specific IgG1 and proinflammatory cytokine production in nicotinic acetylcholine receptor alpha7 subunit gene knockout mice. J Neuroimmunol 2007; 189: 69–74.
    1. Koval L, Lykhmus O, Zhmak M, et al. Differential involvement of alpha4beta2, alpha7 and alpha9alpha10 nicotinic acetylcholine receptors in B lymphocyte activation in vitro. Int J Biochem Cell Biol 2011; 43: 516–524.
    1. Beckmann J, Lips KS. The non-neuronal cholinergic system in health and disease. Pharmacology 2013; 92: 286–302.
    1. Elhusseiny A, Hamel E. Muscarinic–but not nicotinic–acetylcholine receptors mediate a nitric oxide-dependent dilation in brain cortical arterioles: a possible role for the M5 receptor subtype. J Cereb Blood Flow Metab 2000; 20: 298–305.
    1. Felder CC, Bymaster FP, Ward J, et al. Therapeutic opportunities for muscarinic receptors in the central nervous system. J Med Chem 2000; 43: 4333–4353.
    1. Sharma G, Vijayaraghavan S. Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proc Natl Acad Sci USA 2001; 98: 4148–4153.
    1. Wess J, Duttaroy A, Zhang W, et al. M1-M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Receptors Channels 2003; 9: 279–290.
    1. Badheka D, Borbiro I, Rohacs T. Transient receptor potential melastatin 3 is a phosphoinositide-dependent ion channel. J Gen Physiol 2015; 146: 65–77.
    1. Nilius B, Owsianik G, Voets T, et al. Transient receptor potential cation channels in disease. Physiol Rev 2007; 87: 165–217.
    1. Nilius B, Biro T. TRPV3: a ‘more than skinny’ channel. Exp Dermatol 2013; 22: 447–452.
    1. Nilius B, Biro T, Owsianik G. TRPV3: time to decipher a poorly understood family member!. J Physiol 2014; 592: 295–304.
    1. Nilius B, Owsianik G. The transient receptor potential family of ion channels. Genome Biol 2011; 12: 218–218.
    1. Nilius B, Szallasi A. Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. Pharmacol Rev 2014; 66: 676–814.
    1. Nilius B, Voets T. The puzzle of TRPV4 channelopathies. EMBO Rep 2013; 14: 152–163.
    1. Vennekens R, Menigoz A, Nilius B. TRPs in the brain. Rev Physiol Biochem Pharmacol 2012; 163: 27–64.
    1. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med 2000; 160: 221–227.
    1. Allen J, Murray A, Di Maria C, et al. Chronic fatigue syndrome and impaired peripheral pulse characteristics on orthostasis–a new potential diagnostic biomarker. Physiol Meas 2012; 33: 231–241.
    1. Brenu EW, Ashton KJ, van Driel M, et al. Cytotoxic lymphocyte microRNAs as prospective biomarkers for chronic fatigue syndrome/myalgic encephalomyelitis. J Affect Disord 2012; 141: 261–269.
    1. Brenu EW, Huth TK, Hardcastle SL, et al. Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis. Int Immunol 2014; 26: 233–242.
    1. Brenu EW, Staines DR, Baskurt OK, et al. Immune and hemorheological changes in chronic fatigue syndrome. J Transl Med 2010; 8: 1–1.
    1. Brenu EW, van Driel ML, Staines DR, et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med 2012; 10: 88–88.
    1. Brenu EW, van Driel ML, Staines DR, et al. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Transl Med 2011; 9: 81–81.
    1. DeLuca J, Johnson SK, Beldowicz D, et al. Neuropsychological impairments in chronic fatigue syndrome, multiple sclerosis, and depression. J Neurol Neurosurg Psychiatry 1995; 58: 38–43.
    1. Hoad A, Spickett G, Elliott J, et al. Postural orthostatic tachycardia syndrome is an under-recognized condition in chronic fatigue syndrome. QJM 2008; 101: 961–965.
    1. Klimas NG, Salvato FR, Morgan R, et al. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990; 28: 1403–1410.
    1. Lewis I, Pairman J, Spickett G, et al. Clinical characteristics of a novel subgroup of chronic fatigue syndrome patients with postural orthostatic tachycardia syndrome. J Intern Med 2013; 273: 501–510.
    1. Medow MS, Stewart JM. The postural tachycardia syndrome. Cardiol Rev 2007; 15: 67–75.
    1. Nisenbaum R, Reyes M, Mawle AC, et al. Factor analysis of unexplained severe fatigue and interrelated symptoms: overlap with criteria for chronic fatigue syndrome. Am J Epidemiol 1998; 148: 72–77.
    1. Marshall-Gradisnik S, Smith P, Nilius B, et al. Examination of single nucleotide polymorphisms in acetylcholine receptors in chronic fatigue syndrome patients. Immunol Immunogenet Insights 2015; 7: 7–7.
    1. Marshall-Gradisnik SM, Huth TK, Chacko A, et al. Natural killer cell cytotoxicity and single nucleotide polymorphisms in transient receptor potential ion channel and acetylcholine receptor genes of isolated natural killer cells in myalgic encephalomyelitis/chronic fatigue syndrome patients. Clinical Application of Genetics (in review) 2015. .
    1. Nguyen T, Staines D, Nilius B, et al. Characterisation of transient receptor potential melastatin 3 ion channel and intracellular cell signalling in B and NK cells from patients with chronic fatigue syndrome. Journal of translational medicine (in review) 2015. .
    1. Loebel M, Grabowski P, Heidecke H, et al. Antibodies to ß adrenergic and muscarinic cholinergic receptors in patients with chronic fatigue syndrome. Brain Behav Immun 2016; 52: 32–39.
    1. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group. Ann Intern Med 1994; 121: 953–959.
    1. .
    1. Marshall-Gradisnik SM, Smith P, Brenu EW, et al. Examination of single nucleotide polymorphisms (SNPs) in transient receptor potential (TRP) Ion channels in chronic fatigue syndrome patients. Immunol Immunogenet Insights 2015; 2015: 1–6.
    1. Kang SW, Wahl MI, Chu J, et al. PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization. EMBO J 2001; 20: 5692–5702.
    1. Su TT, Guo B, Kawakami Y, et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 2002; 3: 780–786.
    1. Li W, Llopis J, Whitney M, et al. Cell-permeant caged InsP3 ester shows that Ca2+ spike frequency can optimize gene expression. Nature 1998; 392: 936–941.
    1. Dolmetsch RE, Xu K, Lewis RS. Calcium oscillations increase the efficiency and specificity of gene expression. Nature 1998; 392: 933–936.
    1. Negulescu PA, Shastri N, Cahalan MD. Intracellular calcium dependence of gene expression in single T lymphocytes. Proc Natl Acad Sci U S A 1994; 91: 2873–2877.
    1. Kawashima K, Fujii T, Moriwaki Y, et al. Reconciling neuronally and nonneuronally derived acetylcholine in the regulation of immune function. Ann N Y Acad Sci 2012; 1261: 7–17.
    1. Kawashima K, Fujii T, Moriwaki Y, et al. Critical roles of acetylcholine and the muscarinic and nicotinic acetylcholine receptors in the regulation of immune function. Life Sci 2012; 91: 1027–1032.
    1. Wessler IK and Kirkpatrick CJ. Activation of muscarinic receptors by non-neuronal acetylcholine. Handb Exp Pharmacol 2012: 469–491.
    1. Fujii T, Takada-Takatori Y, Kawashima K. Regulatory mechanisms of acetylcholine synthesis and release by T cells. Life Sci 2012; 91: 981–985.
    1. Huijbers MG, Lipka AF, Plomp JJ, et al. Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis. J Intern Med 2014; 275: 12–26.
    1. Tobin G, Giglio D, Lundgren O. Muscarinic receptor subtypes in the alimentary tract. J Physiol Pharmacol 2009; 60: 3–21.
    1. Park K, Haberberger RV, Gordon TP, et al. Antibodies interfering with the type 3 muscarinic receptor pathway inhibit gastrointestinal motility and cholinergic neurotransmission in Sjogren’s syndrome. Arthritis Rheu 2011; 63: 1426–1434.
    1. Wang H, Lu Y, Wang Z. Function of cardiac M3 receptors. Auton Autacoid Pharmacol 2007; 27: 1–11.
    1. Wang S, Han HM, Jiang YN, et al. Activation of cardiac M3 muscarinic acetylcholine receptors has cardioprotective effects against ischaemia-induced arrhythmias. Clin Exp Pharmacol Physiol 2012; 39: 343–349.
    1. Molina J, Rodriguez-Diaz R, Fachado A, et al. Control of insulin secretion by cholinergic signaling in the human pancreatic islet. Diabetes 2014; 63: 2714–2726.
    1. Ruze de Azua I, Gautam D, Jain S, et al. Critical metabolic roles of β-cell M 3 muscarinic acetylcholine receptors. Life Sci 2012; 91: 986–991.
    1. Gautam D, Han SJ, Hamdan FF, et al. A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab 2006; 3: 449–461.
    1. Racké K, Juergens UR, Matthiesen S. Control by cholinergic mechanisms. Eur J Pharmacol 2006; 533: 57–68.
    1. Kuersten S, Goodwin EB. The power of the 3’ UTR: translational control and development. Nat Rev Genet 2003; 4: 626–637.
    1. Albuquerque EX, Pereira EF, Alkondon M, et al. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009; 89: 73–120.
    1. Changeux JP. The nicotinic acetylcholine receptor: the founding father of the pentameric ligand-gated ion channel superfamily. J Biol Chem 2012; 287: 40207–40215.
    1. Hardcastle SL, Brenu E, Johnston S, et al. Analysis of the relationship between immune dysfunction and symptom severity in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). J Clin Cell Immunol 2014; 5: 4172–4172.
    1. Vijayaraghavan S, Sharma G. Editorial: Brain cholinergic mechanisms. Front Synaptic Neurosci 2015; 7: 14–14.
    1. Boysen NC, Dragon DN, Talman WT. Parasympathetic tonic dilatory influences on cerebral vessels. Auton Neurosci 2009; 147: 101–104.
    1. Gu Z, Yakel JL. Timing-dependent septal cholinergic induction of dynamic hippocampal synaptic plasticity. Neuron 2011; 71: 155–165.
    1. Seigneur J, Kroeger D, Nita DA, et al. Cholinergic action on cortical glial cells in vivo. Cereb Cortex 2006; 16: 655–668.
    1. Navarrete M, Perea G, Fernadez de Sevilla D, et al. Astrocytes mediate in vivo cholinergic-induced synaptic plasticity. PLoS-Biol 2012; 10: e1001259–e1001259.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться